FX1
A potent, specific BCL6 BTB domain inhibitor with Kd of 7 uM, binds with a greater affinity than the natural BCL6 ligand SMRT (Kd=30 uM) ; exhibits 10-fold greater inhibitory activity against the BCL6 BTB domain in reporter assays with IC50 of 35 uM, displays good selectivity against a panel of 50 different kinases; disrupts formation of the BCL6 repression complex, reactivates BCL6 target genes, suppresses ABC-DLBCL cells in vitro and in vivo, as well as primary human ABC-DLBCL specimens ex vivo.
Product Specifications
CAS Number
1426138-42-2
Product Name Alternative
FX-1 | FX 1 | BCL6 inhibitor FX1
Purity
>98% (HPLC)
Solubility
DMSO: 30 mg/mL, Need Ultrasonic (< 1 mg/ml refers to the product slightly soluble or insoluble)
Smiles
O=C (O) CCN (C/1=O) C (SC1=C2C (NC3=C/2C=C (Cl) C=C3) =O) =S
Molecular Formula
C14H9ClN2O4S2
Molecular Weight
368.806
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
(Z) -3- (5- (5-chloro-2-oxoindolin-3-ylidene) -4-oxo-2-thioxothiazolidin-3-yl) propanoic acid
Available Sizes
Explore Other Products
Browse additional items from our catalog
